Spironolactone in dermatology: uses in acne and beyond.
Acne Vulgaris
/ drug therapy
Adult
Alopecia
/ drug therapy
Dermatology
/ standards
Drug Monitoring
/ methods
Female
Hidradenitis Suppurativa
/ drug therapy
Hirsutism
/ drug therapy
Humans
Hyperkalemia
/ chemically induced
Hypotension
/ chemically induced
Middle Aged
Mineralocorticoid Receptor Antagonists
/ adverse effects
Retrospective Studies
Spironolactone
/ adverse effects
Treatment Outcome
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
accepted:
23
05
2020
pubmed:
28
8
2020
medline:
29
7
2021
entrez:
27
8
2020
Statut:
ppublish
Résumé
Spironolactone is a synthetic aldosterone receptor antagonist, with a role off-label in various dermatological conditions. Its antiandrogenic properties make it suitable for diseases in which excess androgen production results in unwanted and psychologically distressing manifestations in susceptible females. Treatment with spironolactone aims to attenuate androgen-mediated conditions including acne, hidradenitis suppurativa, female pattern hair loss and hirsutism. We discuss the emerging utility of spironolactone in dermatology, its potential adverse effects and considerations for monitoring.
Substances chimiques
Mineralocorticoid Receptor Antagonists
0
Spironolactone
27O7W4T232
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
986-993Informations de copyright
© 2020 British Association of Dermatologists.
Références
Shaw JC. Spironolactone in dermatologic therapy. J Am Acad Dermatol 1991; 24: 236-43.
Layton AM, Eady EA, Whitehouse H et al. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. Am J Clin Dermatol 2017; 18: 169-91.
Grandhi R, Alikhan A. Spironolactone for the treatment of acne: a 4-year retrospective study. Dermatol 2017; 233: 141-4.
Isvy-Joubert A, Nguyen JM, Gaultier A et al. Adult female acne treated with spironolactone: a retrospective data review of 70 cases. Eur J Dermatol 2017; 27: 393-8.
Roberts EE, Nowsheen S, Davis MD et al. Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16302
Barbieri JS, Choi JK, Mitra N, Margolis DJ. Frequency of treatment switching for spironolactone compared to oral tetracycline-class antibiotics for women with acne: a retrospective cohort study 2010-16. J Drugs Dermatol 2018; 17: 632-8.
Basu P, Elman SA, Abudu B et al. High-dose spironolactone for acne in patients with polycystic ovarian syndrome: a single institution retrospective study. J Am Acad Dermatol 2019; S0190-9622(19)32497-1.
Levy LL, Emer JJ. Female pattern alopecia: current perspectives. Int J Women's Health 2013; 5: 541-56.
Burns LJ, De Souza B, Flynn E et al. Spironolactone for treatment of female pattern hair loss. J Am Acad Dermatol 2020; 83: 276-8
Famenini S, Slaught C, Duan L, Goh C. Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. J Am Acad Dermatol 2015; 73: 705-6.
Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol 2018; 57: 104-9.
Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 2005; 152: 466-73.
Azarchi S, Bienenfeld A, Sicco KL et al. Androgens in women: hormone-modulating therapies for skin disease. J Am Acad Dermatol 2019; 80: 1509-21.
Golbari NM, Porter ML, Kimball AB. Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2019; 80: 114-19.
Lee A, Fischer G. A case series of 20 women with hidradenitis suppurativa treated with spironolactone. Aust J Dermatol 2015; 56: 192-6.
Quinlan C, Kirby B, Hughes R. Spironolactone therapy for hidradenitis suppurativa. Clin Exp Dermatol 2020; 45: 464-5.
Koulouri O, Conway GS. A systematic review of commonly used medical treatments for hirsutism in women. Clin Endocrinol 2008; 68: 800-5.
Kelekci KH, Kelekci S, Yengel I et al. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens. J Dermatol Treat 2012; 23: 177-83.
Kelestimur F, Everest H, Unluhizarci K et al. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Eur J Endocrinol 2004; 150: 351-4.
Cumming DC, Yang JC, Rebar RW et al. Treatment of hirsutism with spironolactone. JAMA 1982; 247: 1295-8.
Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol 2000; 19: 587-94.
Kim GK, Del Rosso JQ. Oral spironolactone in post-teenage female patients with acne vulgaris: practical considerations for the clinician based on current data and clinical experience. J Clin Aesthet Dermatol 2012; 5: 37-50.
Shaw JC, White LE. Long-term safety of spironolactone in acne: results of an 8-year follow-up study. J Cutan Med Surg 2002; 6: 541-5.
Gulmez SE, Lassen AT, Aalykke C et al. Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. Br J Clin Pharmacol 2008; 66: 294-9.
Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol 2015; 151: 941-4.
Thiede RM, Rastogi S, Nardone B et al. Hyperkalemia in women with acne exposed to oral spironolactone: a retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program. Int J Womens Dermatol 2019; 5: 155-7.
Wu JL, Hou DY, Ma GL et al. Effects of long-term low-dose spironolactone treatment in patients with New York Heart Association functional class II heart failure: a 10-year prospective study. Int J Clin Exp Med 2016; 9: 15689-98.